A FIDELITY Analysis on Finerenone With SGLT-2i and GLP-1RA in CKD
The concomitant use of finerenone with SGLT-2i and/or GLP-1RA demonstrated potential synergistic effects on preserving kidney function and reducing blood pressure versus placebo in people with CKD and T2D.
Authors
- Stefan D. Anker (ORCID: https://orcid.org/0000-0002-0805-8683)
- Marc Lambelet
- Gerasimos S Filippatos (ORCID: https://orcid.org/0000-0002-5640-0332)
- Katja Rohwedder
- Luís M. Ruilope (ORCID: https://orcid.org/0000-0001-6278-7951)
- Meike Brinker (ORCID: https://orcid.org/0000-0002-1560-9535)
- Peter R Rossing (ORCID: https://orcid.org/0000-0002-1531-4294)
- Ajay Singh (ORCID: https://orcid.org/0000-0003-2933-4058)
- Youssef M.K. Farag (ORCID: https://orcid.org/0000-0003-1692-1851)
- Bertram Pitt
- Christiane Ahlers
Institutions
- University of Copenhagen (DK)
- Steno Diabetes Centers (DK)
- Harvard University (US)
- Johns Hopkins University (US)
- National and Kapodistrian University of Athens (GR)
- University of Michigan (US)
- Centro de Investigación en Red en Enfermedades Cardiovasculares (ES)
- Hospital Universitario 12 De Octubre (ES)
- German Centre for Cardiovascular Research (DE)
- Dana-Farber Brigham Cancer Center (US)
- Bayer (Germany) (DE)
- Charité - Universitätsmedizin Berlin (DE)
- Universidad Europea de Madrid (ES)
Publication Details
- Journal
- Kidney International Reports
- Published
- 2025-11-28
- DOI
- https://doi.org/10.1016/j.ekir.2025.10.032
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29
Funders
- Bayer